XT
TPST icon

XTX Topco’s Tempest Therapeutics TPST Stock Holding History

XTX Topco’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,370
Closed -$134K – 3120
2024
Q4 		$134K Buy
12,370
+10,525
+570% +$136K 0.01% 1702
2024
Q3 		$33.6K Buy
+1,845
New +$37.8K ﹤0.01% 1763
2024
Q2 		– Sell
-829
Closed -$42.1K – 2470
2024
Q1 		$42.1K Buy
+829
New +$41.9K 0.01% 1500

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

XTX Topco's TPST Position: Q1 2025 in Review

XTX Topco sold out of Tempest Therapeutics (TPST) in Q1 2025, closing a stake of 12,370 shares — an estimated $134K sold.

XTX Topco first reported a position in TPST in Q1 2024 and held it in 3 quarters. The position peaked at $134K in Q4 2024. 23 funds tracked by Wall St. Rank hold TPST as of Q1 2025.

  • XTX Topco reported no remaining Tempest Therapeutics position as of Q1 2025 after selling out during the quarter.
  • XTX Topco sold 12,370 Tempest Therapeutics shares in Q1 2025, an estimated $134K.
  • XTX Topco first reported a position in Tempest Therapeutics in Q1 2024 and held it in 3 quarters.
  • XTX Topco's Tempest Therapeutics position peaked at $134K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2025.

Based on XTX Topco's 13F filing for Q1 2025, filed 8 May 2025.